• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    USANA Health Sciences Provides Preliminary Fiscal Year 2025 Net Sales and Issues Initial Fiscal Year 2026 Net Sales Outlook

    1/12/26 6:15:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email

    USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary fiscal year 2025 net sales and initial net sales guidance for fiscal year 2026 ahead of its presentation at the 28th Annual ICR Conference. At the conference, Doug Hekking, CFO, and Walter Noot, COO, will discuss USANA's strategy, including the Company's initial fiscal year 2026 sales outlook.

    Preliminary Fiscal Year 2025 Net Sales Results

    The Company currently anticipates fiscal year 2025 consolidated net sales of approximately $925 million, ahead of its most recently issued guidance of approximately $920 million.

    Initial Fiscal Year 2026 Net Sales Outlook

    The Company is issuing its initial net sales outlook for fiscal year 2026 in the range of $925 million to $1.0 billion.

    The Company's initial fiscal 2026 net sales outlook reflects:

    • Net sales from USANA, our core nutritional business, of $720 to $765 million (compared to preliminary net sales for fiscal 2025 of approximately $777 million);
    • Net sales from Hiya of $140 to $155 million (compared to preliminary net sales for fiscal 2025 of approximately $132 million);
    • Net sales from Rise Wellness of $65 to $80 million (compared to preliminary net sales for fiscal 2025 of approximately $16 million); and
    • Fiscal 2026 is a 52-week year, one week less of net sales compared to fiscal 2025 (impacts the core nutritional business).

    Rise Wellness (comprising two brands – Rise Bar and Protein Pop) experienced meaningful year-over-year net sales growth in 2025 and expects accelerated growth during fiscal 2026. Consequently, operating margins in this business are expected to be at breakeven in fiscal 2026 as it invests in strategic activities to drive future growth.

    Additionally, the Company is making meaningful investments at both Rise Wellness and Hiya in inventory, capital expenditures and other working capital needs to support the early growth stages of these businesses.

    Participation at the 28th Annual ICR Conference:

    The Company will be participating in the 28th Annual ICR Conference in Orlando, FL on January 12-13, 2026. Doug Hekking, CFO, and Walter Noot, COO, are scheduled to present at 3:30PM ET on January 12, 2026. A live audio webcast of the presentation will be available on USANA's website at https://ir.usana.com and a replay will be available on the same day.

    Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call

    The Company's preliminary financial results, initial fiscal 2026 sales outlook and views on market trends observed in the fourth quarter of 2025 are based on information available as of the date of this release. The estimates provided in this release are preliminary and will be updated during our fourth quarter and fiscal year 2025 earnings release, scheduled after the close of market on Tuesday, February 17, 2026. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's website (https://ir.usana.com) under the News/Events section of the site. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, February 18, 2026 at 11:00 AM ET. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com.

    Safe Harbor

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements are based on current plans, expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as "expect," "enhance," "drive," "anticipate," "intend," "improve," "promote," "should," "believe," "continue," "plan," "goal," "opportunity," "estimate," "predict," "may," "will," "could," and "would," and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding Hiya's and Rise Wellness's growth in 2026 and continued growth in the future; statements about the Company's long-term growth; and the statements under the sub-heading "Fiscal Year 2026 Outlook." Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including: risks relating to global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; the ability of Hiya and Rise Wellness to drive brand awareness, customer acquisition and sales channel expansion; the reliance of our direct selling business upon our network of independent Brand Partners; risk that our Brand Partner compensation plan, or changes that we make to the compensation plan, will not produce desired results, benefit our business or, in some cases, could harm our business; risk associated with our launch of new products or reformulated existing products; risks related to governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets, including potential adverse impact from tariffs, trade policies or other international disputes by and among the United States, China, or other markets that are important to the Company; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict and the conflict in Israel; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with early stage operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; the diversion of the attention of the management teams of USANA, Hiya and Rise Wellness from ongoing business operations; the ability of to retain key personnel of USANA, Hiya, and Rise Wellness; the ability to realize the benefits of the Hiya acquisition, including efficiencies and cost synergies; the ability to successfully integrate Hiya's business with USANA's business, at all or in a timely manner; and the amount of the costs, fees, expenses and charges related to the acquisition. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's expectations, except as required by law.

    About USANA

    USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Brand Partners and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found at www.usana.com. USANA also owns a 78.8% controlling ownership stake in Hiya Health Products, a children's health and wellness company and a 100% interest in Rise Wellness. Hiya and Rise Wellness offer a variety of clean-label health products. More information on Hiya can be found at www.hiyahealth.com. More information on Rise Wellness can be found on www.risebar.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260112264546/en/

    Investor contact:

    Andrew Masuda

    Investor Relations

    (801) 954-7201

    investor.relations@usanainc.com

    Media contact:

    Sarah Searle

    (801) 954-7626

    media@usanainc.com

    Get the next $USNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    USANA's Celavive Contouring Face & Neck Crème Named Among Canada's Top Skincare Products

    TORONTO, June 8, 2026 /CNW/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, announced today that its Celavive Contouring Face & Neck Crème has earned top recognition from The Beauty Awards Canada as one of the best skincare products in the country. The Contouring Face & Neck Crème won in the Best Neck & Décolleté Cream category. "Recognition from The Beauty Awards Canada is a significant achievement for our Celavive skincare line," said Brent Neidig, USANA's chief commercial officer. "The Contouring Face & Neck Crème was developed to deliver a luxurious skincare experience backed by innovative science, an

    6/8/26 6:46:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Earns Dual Best of State Honors for Product Innovation and Development

    USANA's CellSentials and Research and Development team honored at the awardsSALT LAKE CITY, June 4, 2026 /PRNewswire/ -- USANA, a leader in global nutrition, earned two Best of State awards in Salt Lake City, Utah, recognizing its CellSentials supplements and Research and Development team. USANA took home two Best of State medals this year in the following categories:Dietary Supplement—USANA CellSentials took home this honor for the tenth consecutive year Research and Development—USANA's R&D team won for the eighth timeTo learn more about USANA and its award-winning products, please visit USANA.com. "We are beyond honored to re

    6/4/26 6:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Kevin Guest Encourages Professionals to Prioritize Wellness During Professional Wellness Month

    USANA CEO says small daily habits can strengthen health, improve workplace culture, and help others thriveSALT LAKE CITY, June 1, 2026 /CNW/ -- As Professional Wellness Month begins in June, Kevin Guest, Chairman and CEO of USANA Health Sciences (NYSE:USNA), is encouraging professionals, leaders, and organizations to make wellness a priority both at work and at home. He says healthier habits create stronger people, stronger teams, and stronger communities. Professional Wellness Month highlights the connection between personal well-being and workplace success. Research continues

    6/1/26 7:18:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sidoti initiated coverage on USANA

    Sidoti initiated coverage of USANA with a rating of Buy

    6/23/23 9:12:38 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA downgraded by Jefferies with a new price target

    Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

    7/7/22 9:35:48 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    DA Davidson initiated coverage on USANA with a new price target

    DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

    4/14/22 7:45:27 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fleming John Turman sold $43,928 worth of shares (2,450 units at $17.93), decreasing direct ownership by 37% to 4,230 units (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    6/1/26 4:36:41 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF PEOPLE OFFICER Jones Paul A. sold $129,106 worth of shares (6,813 units at $18.95), decreasing direct ownership by 55% to 5,561 units (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    5/29/26 1:39:23 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF FINANCIAL OFFICER Iiekking G Doug sold $100,513 worth of shares (5,360 units at $18.75), closing all direct ownership in the company (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    5/28/26 12:17:40 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    SEC Filings

    View All

    USANA Health Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    5/20/26 4:24:08 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by USANA Health Sciences Inc.

    10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    5/12/26 4:35:39 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    5/5/26 4:17:42 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Financials

    Live finance-specific insights

    View All

    USANA Health Sciences Reports First Quarter 2026 Results

    Company Continues to Make Significant Progress on Transformation to Becoming a Leading Omnichannel Health and Wellness Platform USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended April 4, 2026. Key Financial Results First Quarter 2026 vs. First Quarter 2025 Net sales of $250 million versus $250 million. Net earnings of $7.5 million versus $9.4 million. Diluted EPS of $0.41 as compared with $0.49. Adjusted diluted EPS(1) of $0.61 as compared with $0.73. Adjusted EBITDA(2) of $28.4 million versus $29.8 million. Core Nutritional Active Customers of 404,000 versus 459,000. Hiya Active Monthly Subscribers of 186

    5/5/26 4:15:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Schedules First Quarter 2026 Earnings Release and Conference Call

    USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter 2026 results will be released after the close of market on Tuesday, May 5, 2026. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, May 6, 2026 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures high-

    4/15/26 7:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Next-Generation Platforms Scale Across Energy, Wellness, and Smokeless Consumer Segments

    Issued on behalf of Doseology Sciences Inc.Equity-Insider.com VANCOUVER, BC, March 5, 2026 /CNW/ -- Consumers are voting with their wallets, and zero-sugar is winning. Zero-sugar beverages are driving 6x more dollar growth than regular varieties as buyers actively choose clean-label products with natural sweeteners and functional ingredients[1]. The global market is forecast to expand from $350 billion in 2024 toward $500 billion by 2029, fueled by health-conscious consumers who want naturally functional products without heavy processing[1]. This structural shift is creating validated demand for precision-dosed, portable formats across energy and wellness categories, positioning Doseology Sc

    3/5/26 9:00:00 AM ET
    $HLF
    $NHTC
    $NMTC
    Other Pharmaceuticals
    Health Care
    Consumer Specialties
    Consumer Discretionary

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/24 10:49:58 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/23 11:26:45 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/11/22 3:48:24 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    View All

    Kevin Guest Returns to USANA Health Sciences as CEO

    USANA Health Sciences, Inc. (NYSE:USNA) announced today a leadership transition as part of the Company's ongoing commitment to accelerating growth and enhancing shareholder value. Kevin Guest is returning to lead the Company as Chief Executive Officer, effective immediately. Mr. Guest, who has spent more than three decades at the Company, including eight years as CEO and the last three years as Executive Chairman, has agreed to again serve as USANA's CEO and will continue serving as Chairman. Mr. Guest succeeds Jim Brown, who has stepped down from his position of CEO and President. "We thank Jim for his contributions and his leadership over the past 19 years and in his role as CEO over th

    1/8/26 9:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Solstice Advance Materials and Qnity Electronics Set to Join S&P 500; Others to Join S&P SmallCap 600

    NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c

    10/27/25 6:10:00 PM ET
    $CAL
    $DD
    $EMN
    Shoe Manufacturing
    Consumer Discretionary
    Major Chemicals
    Industrials

    USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

    SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

    4/1/25 7:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care